Synapse - Mark Kris

Results (869)

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Journal Article

Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Therapeutic potential of afatinib for cancers with ERBB2 (HER2) transmembrane domain mutations G660D and V659E

Journal Article

Yamamoto, H.; Toyooka, S.; Ninomiya, T.; Matsumoto, S.; Kanai, M.; Tomida, S.; Kiura, K.; Muto, M.; Suzawa, K.; Desmeules, P.; more...
The Oncologist (2018)

Fulltext@MSK | Save

Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer

Journal Article

Arbour, K. C.; Jordan, E.; Kim, H. R.; Dienstag, J.; Yu, H. A.; Sanchez-Vega, F.; Lito, P.; Berger, M.; Solit, D. B.; Hellmann, M.; more...
Clinical Cancer Research (2018)

Fulltext@MSK | Save

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

Journal Article

Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
Cancer (2018)

Fulltext@MSK | Save

A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC)

Meeting Abstract

Owen, D. H.; Bunn, P. A.; Johnson, B. E.; Kwiatkowski, D. J.; Kris, M. G.; Wistuba, I. I.; Gandhi, M.; Phan, S.; Shames, D. S.; Schulze, K.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies

Meeting Abstract

Offin, M.; Olah, Z. T.; Sabari, J. K.; Tandon, N.; Feldman, D.; Abou-Alfa, G. K.; Lok, B. H.; Burck, N.; Tarcic, G.; Miron, B.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study

Meeting Abstract

Lai, W. C. V.; Lebas, L.; Milia, J.; Barnes, T. A.; Gautschi, O.; Peters, S.; Ferrara, R.; Ni, A.; Sabari, J. K.; Clarke, S. J.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing

Meeting Abstract

Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers

Meeting Abstract

Drilon, A. E.; Filleron, T.; Bergagnini, I.; Milia, J.; Hatzoglou, V.; Velcheti, V.; Besse, B.; Mok, T.; Awad, M. M.; Wolf, J.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC)

Meeting Abstract

Dagogo-Jack, I.; Santini, F.; Eng, J.; Yeap, B. Y.; Izar, B.; Chin, E.; Litvak, A.; Jones, D. R.; Kris, M. G.; Shaw, A. T.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save